Richard C. Barry

Richard C. Barry

Auto-generated profile, based on publicly available information

Richard C. Barry

Blink Eye Clinic, Sydney, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2013 in Toxicological Sciences
Verified
Journal Article
Closed access
PDF file
ISIrvin R. Schultz
Irvin R. Schultz
JNJames J. Nagler
James J. Nagler
PSPenny Swanson
Penny Swanson
DWDavid Wunschel
David Wunschel
ASAnn D. Skillman
Ann D. Skillman
RBRichard Barry
Richard Barry
The toxicokinetics of trenbolone was characterized during 500ng/l water exposures in female rainbow trout (Oncorhynchus mykiss) and fathead minnows (Pimephales promelas). Related experiments measured various toxicodynamic effects of exposure. In both species, trenbolone was rapidly absorbed from the water and reached peak plasma levels within 8h of exposure. Afterwards, trenbolone concentrations in trout (66–95ng/ml) were 2–6 times higher compared with minnows (15–29ng/ml), which was attributable to greater plasma binding in trout. During water exposures, circulating levels of estradiol (E2) rapidly decreased in both species to a concentration that was 25%–40% of control values by 8–24h of exposure and then remained relatively unchanged for the subsequent 6 days of exposure. In trout, changes in circulating levels of follicle-stimulating hormone were also significantly greater after trenbolone exposure, relative to controls. In both species, the pharmacokinetics of injected E2-d3 was altered by trenbolone exposure with an increase in total body clearance and a corresponding decrease in elimination half-life. The unbound percentage of E2 in trout plasma was 0.25%, which was similar in pre- or postvitellogenic female trout. Subsequent incubation with trenbolone caused the unbound percentage to significantly increase to 2.4% in the previtellogenic trout plasma. iTRAQ-based toxicoproteomic studies in minnows exposed to 5, 50, and 500ng/l trenbolone identified a total of 148 proteins with 19 downregulated including vitellogenin and 18 upregulated. Other downregulated proteins were fibrinogens, α-2-macroglobulin, and transferrin. Upregulated proteins included amine oxidase, apolipoproteins, parvalbumin, complement system proteins, and several uncharacterized proteins. The results indicate trenbolone exposure is a highly dynamic process in female fish with uptake and tissue equilibrium quickly established, leading to both rapid and delayed toxicodynamic effects.

1 November 2021 in Translational Vision Science & Technology
Verified
Journal Article
Open access
PDF file
Bhim Bahadur RaiBhim Bahadur Rai
Bhim Bahadur Rai
Ted MaddessTed Maddess
Ted Maddess
CCCorinne Carle
Corinne Carle
EREmilie M.F. Rohan
Emilie M.F. Rohan
JKJoshua Van Kleef
Joshua Van Kleef
FSFaran Sabeti
Faran Sabeti
Purpose: To compare per-region macular sensitivity and delay from objective perimetry with Matrix perimetry and retinal thickness in mild diabetic macular edema (DMO). Methods: Thirty-three patients with type 2 diabetes (T2D) aged 59.2 ± 10.5 years participated in a longitudinal study. Macular thickness, sensitivities and delays from the objectiveFIELD Analyzer (OFA), and Matrix perimeter sensitivities were mapped onto a common spatial layout to compute per-region correlations between structure/function measures. A generalized linear mixed-effects logistic regression model determined which variables contributed to clinical diagnosis of DMO. Results: For OFA, the mean sensitivity differences compared with normal in patients with T2D were negative and the mean delay differences positive, indicating lowered sensitivities and prolonged delays, both increasing with diabetes duration. Shorter diabetes duration could produce either localized peripheral hypersensitivities or shorter delays. Functional change could occur when retinal thickness was stable. Peripheral macular thickness correlated with central and peripheral OFA sensitivity and delay, all P < 0.0012 in DMO and a median of P = 0.001 without DMO; this was not true for Matrix sensitivities. The logistic model determined that peripheral thickness, OFA sensitivity (P = 0.043), and time in the study (P = 0.001) contribute independently to the odds of DMO versus no DMO. Conclusions: Mean sensitivities decreased and mean delays increased with duration of diabetes. Peripheral macular thickness correlated significantly with central and peripheral macular OFA sensitivity and delay. Peripheral macular thickness and functional measures may provide sensitive prognostic data. Translational Relevance: Functional loss can precede structural change in DMO, so including such functional assessment for deciding on treatment may be beneficial.

14 March 2024 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Open access
PDF file
Bhim Bahadur RaiBhim Bahadur Rai
Bhim Bahadur Rai
FSFaran Sabeti
Faran Sabeti
JKJoshua Van Kleef
Joshua Van Kleef
CCCorinne Carle
Corinne Carle
EREmilie M.F. Rohan
Emilie M.F. Rohan
Ted MaddessTed Maddess
Ted Maddess
Purpose: To compare diagnostic power for different severities of age-related macular degeneration (AMD) of two-dimensional macular pigment optical densities (2D-MPOD) and spatially matched objective perimetry, with standard perimetry and best-corrected visual acuity (BCVA). Methods: The ObjectiveField Analyser (OFA) provided objective perimetry, and a Heidelberg Spectralis optical coherence tomography (OCT) measured 2D-MPOD in AMD patients, both completed twice over 0.99 ± 0.16 years. From each 2D-MPOD image, we extracted 20 regions/macula, matched to the 20 OFA stimuli/macula. For each region, we calculated 7 measures from the 2D-MPOD pixel values and correlated those with OFA sensitivities and delays. We quantified 2D-MPOD changes, the ability of 2D-MPOD and OFA to discriminate AMD stages, and the discriminatory power of Matrix perimetry and BCVA using percentage area under receiver operator characteristic plots (%AUROC). Results: In 58 eyes of 29 subjects (71.6 ± 6.3 years, 22 females), we found significant correlations between 2D-MPOD and OFA sensitivities for Age-Related Eye Disease Studies (AREDS)-3 and AREDS-4 severities. Delays showed significant correlations with AREDS-2. For AREDS-4, correlations extended across all eccentricities. Regression associated with the Bland–Altman plots showed significant changes in 2D-MPOD over the study period, especially variability measures. MPOD per-region medians discriminated AREDS-1 from AREDS-3 eyes at a %AUROC of 80.0 ± 6.3%, outperforming OFA, Matrix perimetry, and BCVA. Conclusions: MPOD changes correlated with central functional changes and significant correlations extended peripherally in later-stage AMD. Good diagnostic power for earlier-stage AMD and significant change over the study suggest that 2D-MPOD and OFA may provide effective biomarkers.

20 April 2026 in Ophthalmology Retina
Verified
Journal Article
Open access
LGLaura Goncalves
Laura Goncalves
YHYohei Hashimoto
Yohei Hashimoto
DBDaniel Barthelmes
Daniel Barthelmes
RBRichard Barry
Richard Barry
APAndreas Pollreisz
Andreas Pollreisz
Pierre-Henry GabriellePierre-Henry Gabrielle
Pierre-Henry Gabrielle
To evaluate visual outcomes observed across visit gaps in patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) therapy in routine clinical practice. Retrospective data analysis from a prospectively designed observational outcomes registry: the Fight Retinal Blindness! (FRB!). Treatment-naïve nAMD eyes receiving intravitreal anti-VEGF therapy (≥1 injection), monitored at least quarterly during the first treatment year, and experiencing a visit gap of ≥6 to 12 months, with subsequent follow-up over the next 9 months (≥3 visits). Visual outcomes were assessed using a segmented linear mixed-effect model. Cumulative incidence and risk factors for visit gaps were evaluated using Aalen-Johansen estimators and Cox regression models. The main outcome was the mean estimated change in VA immediately after the visit gap. Secondary outcomes included the cumulative incidence and associated risk factors of visit gaps. From 3694 eligible eyes for the survival analysis, we tracked 262 (7.1%) eligible eyes experiencing a visit gap for the visual outcome analysis. nAMD-treated eyes experiencing a 6-12 month visit gap had a significant drop in vision immediately after the visit gap, with a mean (95% confidence interval [CI]) estimated change in VA of -4.9 letters (-6.0 to -3.7; P < 0.001). Eyes with active choroidal neovascularization (CNV) lesions (difference -3.9 [-7.1 to -0.3] letters vs. inactive CNV) and without subfoveal macular atrophy (MA) (difference 3.4 [-0.3 to 7.0] letters vs. subfoveal MA) at the last visit before the gap experienced a greater decline in VA after the visit gap. A quarter of the eyes experienced a 6-12 month visit gap at 6.5 years. nAMD eyes with a longer time interval since last injection were more likely to experience a visit gap, while eyes with better VA and that had active CNV with subretinal fluid only at follow-up visits were less likely. Visit gaps were common and associated with a significant visual decline across the visit gap in nAMD eyes treated with anti-VEGF therapy in routine clinical practice.

7 October 2026 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Open access
PDF file
KRKatrin Rudolph
Katrin Rudolph
MRMarianna Rosso
Marianna Rosso
MGMark C. Gillies
Mark C. Gillies
AHAdrian Hunt
Adrian Hunt
LOLouise O'TOole
Louise O'TOole
DBDaniel Barthelmes
Daniel Barthelmes
Background: To report 5‐year outcomes in a cohort of patients who received anti‐VEGF therapy for macular oedema secondary to central retinal vein occlusion (CRVO) in routine clinical practice. Methods: In this retrospective observational study, 593 treatment‐naïve eyes that commenced anti‐VEGF treatment between 1 January 2010, and 2019 were analysed. Outcome measures included mean changes in visual acuity (VA) and central subfield thickness (CST). Results: In the entire cohort (593), the mean VA changed by +8 letters and the mean CST by −298 μm. The entire cohort includes eyes with completed 5‐year follow‐up and non‐completers who dropped out before the end of the observation period. Eyes that completed the 5‐year follow‐up (202/593, 34%) had a mean VA and CST change of +11 letters and −320 μm with a median of 25.5 injections at 39.5 visits. Non‐completers with a final VA of > 70 letters (95/593; 16%) experienced a change in mean VA of +23 letters. In non‐completers with a final VA between 35 and 70 letters (163/593; 27%), the mean VA increased by 12 letters. In non‐completers with a final VA of < 35 letters (133/593; 22%), the mean VA declined by 12 letters. Conclusion: Patients with macular oedema secondary to CRVO who continue treatment can achieve meaningful improvements in vision over an extended period. Patients with initially poor vision tend to have large improvements but the worst outcomes. In contrast, eyes with very good initial VA can achieve excellent functional results and may even stop treatment at some point with adequate therapy.